Last Updated 12/1/14

Combined agenda for the 2014 World Stem Cell Summit and RegMed Capital Conference.

Tuesday, December 2, 2014

9:00a - 10:00a - Offsite Event  -

Pre-Summit Event: Stem Cells — Their Biology and Promise for Regenerative Medicine

This special lecture by Elaine Fuchs, PhD, Rockefeller University is FREE and open to the general public as part of The Stem Cell and Regenerative Medicine Public Education Day, presented by The University of Texas Health Science Center at San Antonio and the World Stem Cell Summit.

LOCATION: 

Holly Auditorium
7703 Floyd Curl Drive
San Antonio, Texas 78229

For more information, click here.

Presenter

 Elaine Fuchs, PhD, Rockefeller University

12:15p - 5:15p Offsite Tour - Meet in Lobby  -

World Stem Cell Summit San Antonio Research Resource Tour

NOTE:  To participate in this event, you must register in advance and must be a paid registrant for the World Stem Cell Summit or the RegMed Capital Conference.

Tour three of San Antonio’s science powerhouses!  Visit world-class facilities with a breadth of resources for potential partners.  On the day before the World Stem Cell Summit begins, December 2, 2014, a pre-registered group will tour BioBridge Global, the Southwest National Primate Research Center (SNPRC) at the Texas Biomedical Research Institute and the Southwest Research Institute (SwRI).  This tour includes Lunch.

For a detailed tour description and to register, click here:
http://worldstemcellsummit.com/research-resource-tour/

1:00p - 4:00p - Offsite Event  -

Pre-Summit Event: Public Education Day

Leading scientists, doctors and patient advocates will present workshops geared toward the general public at The Stem Cell and Regenerative Medicine Public Education Day, presented by The University of Texas Health Science Center at San Antonio and the World Stem Cell Summit.

LOCATION: 
Holly Auditorium
7703 Floyd Curl Drive
San Antonio, Texas  78229

For more information, click here.

 David L. Bales, Texans for Stem Cell Research

 Tiziano Barberi, PhD, Texas Biomedical Research Institute

 Marcel M. Daadi, PhD, Texas Biomedical Research Institute

 Michael R. Davis, MD, FACS, United States Army Institute of Surgical Research

 Cesar O. Freytes, MD, FACC, University of Texas Health Science Center in San Antonio

 Teja Guda, PhD, University of Texas at San Antonio

 Brian P. Hermann, PhD, University of Texas at San Antonio

 Peter J. Hornsby, PhD, University of Texas Health Science Center at San Antonio

 Jon Hudson, GenCure Marrow Donor Program

 Erzsebet Kokovay, PhD, University of Texas Health Science Center at San Antonio

 Donna Lehman, PhD, University of Texas Health Science Center at San Antonio

 Bettie Sue Masters, PhD, D.Sc., MD (Hon.), University of Texas Health Science Center at San Antonio

 John R. McCarrey, PhD, University of Texas at San Antonio

 Mary Pat Moyer, PhD, INCELL Corporation

 Pei Wang, PhD, University of Texas Health Science Center at San Antoni

2:00p - 7:00p  -Salon E Foyer

Preliminary Registration Open – Speakers / Posters / Exhibitors

Preliminary Registration for Speakers, Poster Presenters and Exhibitors.

6:30p - 8:00p  -Sazo’s

Reception

WSCS / RMCC Speaker Reception – By Invitation Only

Reception for Speakers at the World Stem Cell Summit and the RegMed Capital Conference – By Invitation Only!

7:30p - 10:00p  -

World Stem Cell Summit Welcome Party – sponsored by Texas for Stem Cell Research – Offsite Event, Open to All Registered Attendees

Offsite Welcome Party scheduled at:
Henry B. Gonzalez Convention Center
200 Market Street, San Antonio, TX 78205
LDR Room – located on River Level

Featuring Guest Speakers:
- Councilman Ron Nirenburg, District 8, City of San Antonio
- Dr. Doris Taylor, Texas Heart Institute
- Dr. Will Decker, Baylor College of Medicine
- Steve Waters, Chairman, San Antonio Economic Development Foundation (tentative)

Wednesday, December 3, 2014

8:00a - 8:30a  -Salon E-F

Welcome Overview

Partner Greetings

Moderator

 Bernard Siegel, JD, Genetics Policy Institute

Speakers

 William L. Henrich, MD, MACP, The UT Health Science Center at San Antonio

 Norio Nakatsuji, DSc, Institute for Integrated Cell-Material Science (iCeMS), Kyoto University

 Linda Myers, ASCP, MT, SBB, CQA (ASQ), BioBridge Global

 Andre Terzic, MD, PhD, Center for Regenerative Medicine, Mayo Clinic

8:30a - 9:30a  -Salon E-F

Plenary Keynote

Regenerative Medicine: Current Concepts and Changing Trends

Presenter

 Anthony Atala, MD, Wake Forest University Medical Center

9:30a - 10:30a  -Salon E-F

Track Keynote

Discovery

(Bio)Banking on the Future of RegMed: Building Organs is Just Part of it

Presenter

 Doris A. Taylor, PhD, FAHA, FACC, Texas Heart Institute at St. Luke's Episcopal Hospital

9:30a - 10:30a  -Salon A-B

Track Keynote

Regenerative Services & Restorative Medicine

Tissue Repair and Regeneration Using Adipose Tissue as a Biological Resource: Past, Present and Future

Presenter

 Adam J. Katz, MD, FACS, University of Florida College of Medicine

9:30a - 10:30a  -Salon C-D

Panel Discussion

Hot Topics & Future Trends

Global Regulation of Stem Cell Therapies

Moderator

 Rosario Isasi, JD, MPH, McGill University & Genome Quebec Innovation Centre

Speakers

 Satoshi Yasuda, National Institute of Health Sciences

 Timo Faltus, Translational Centre for Regenerative Medicine (TRM)

 Donald W. Fink, Jr., PhD, Center for Biologics Evaluation and Research / US FDA

9:30a - 10:30a  -Conference Room 1-2

Panel Discussion

Innovation Showcase

Missing Link for Successful Trials: The Non-human Primate Imperative

Moderator

 Marcel M. Daadi, PhD, Texas Biomedical Research Institute

Speaker

 Brian P. Hermann, PhD, University of Texas at San Antonio

 Peter J. Hornsby, PhD, University of Texas Health Science Center at San Antonio

 John R. McCarrey, PhD, University of Texas at San Antonio

9:30a - 10:30a  -Conference Room 3-4

Panel Discussion

Reg Med Capital Conference

RegMed & Cell Therapy- Multi-Billion Dollar Industries with Unlimited Potential

Moderator

 Gregory A. Bonfiglio, Proteus Venture Partners

Speakers

 Jane C. Andrews, PhD, Frost & Sullivan

 Gregory A. Bonfiglio, Partner, Proteus Venture Partners

 Chris Mason, MBBS, PhD, FRCS, University College London

9:30a - 10:30a  -Conference Room 17-18

Panel Discussion

Translation & Clinical Trials

Leading Neurological Clinical Trials from Academia and Industry

Moderator

 Thomas P. Zwaka, MD, PhD, Icahn School of Medicine at Mt. Sinai

Speakers

 Nathan P. Staff, MD, PhD, Mayo Clinic

 Anthony J. Windebank, MD, Mayo Clinic

10:30a - 11:00a  -Salon G-M

Break

Exhibits Open / Morning Break

11:00a - 12:30p  -Salon E-F

Concurrent Session

Translation & Clinical Trials

US Military Investment in Regenerative Medicine

Over the past decade, in the shadow of Operation Iraqi Freedom and Operation Enduring Freedom, DoD has taken a leading role in funding regenerative medicine research. From the Armed Forces Institute of Regenerative Medicine to Congressional Directed funds as well as Service specific programs, the goal has been to advance the restoration of wounded service members that have suffered devastating combat injuries. The full spectrum of advances in regenerative medicine as well as complex reconstructive surgery, including reconstructive transplantation, have been leveraged to facilitate the best possible long term outcomes for our warriors. In the face of continued instability in our world, DoD will continue to require intramural and extramural innovation to advance combat casualty care. DoD funding mechanisms represent unique opportunities to advance the science of regenerative medicine while also striving toward the noble goal of optimizing care for our wounded service members.

Moderator

 Michael R. Davis, MD, FACS, United States Army Institute of Surgical Research

Speakers

 Brian Pfister, PhD, MBA, US Army Medical Research and Materiel Command

 Debra Niemeyer, PhD, 59th Medical Wing Joint Base San Antonio

 Anthony J. Windebank, MD, Mayo Clinic

 Michael J. Yaszemski, MD, PhD,, Mayo Clinic

11:00a - 12:30p  -Salon A-B

Panel Discussion

Regenerative Services & Restorative Medicine

Adipose Tissue and SVF

Adipose tissue until recently was considered to be poor grafting material in tissue reconstruction. Pioneering work by Sidney Coleman MD on processing techniques for fat grafting led to its increased use. As adipose tissue grafting became widespread its regenerative properties came to the fore as surgeons noticed unexpected skin rejuvenation, scar resolution, and most remarkably reversal of hitherto intractable conditions such as radiation fibrosis. In the late ’90s under the direction of William Futrell MD at the University of Pittsburgh, Adam Katz MD first isolated and recognized the abundant presence of MSC’s (mesenchymal stem cells) in adipose tissue, thus providing the key to understanding the regenerative potential of Adipose tissue which is contained in its Stromal Vascular Fraction (SVF). Building on this foundation, Peter Rubin MD has created a powerhouse engine of academic research and the central nexus for Adipose tissue and SVF science at the University of Pittsburgh. Bringing SVF technologies to market is a arduous process but William Cimino PhD, CEO of GID has proven autologous SVF therapy is not only market ready, but already being deployed in several countries successfully.

Moderator

 Ricardo Luis Rodriguez, MD, Cosmeticsurg

Speakers

 William W. Cimino, PhD, The GID Group, Inc.

 Adam J. Katz, MD, FACS, University of Florida College of Medicine

 J. Peter Rubin, MD, University of Pittsburgh

11:00a - 12:30p  -Salon C-D

Concurrent Session

Hot Topics & Future Trends

Regenerative Medicine: A New Era of Discovery and Innovation (supported by Mary Ann Liebert, Inc.)

Moderator

 John Sterling, Genetic Engineering & Biotechnology News (GEN)

Speakers

 Marie Csete, MD, PhD, Huntington Medical Research Institute

 Aubrey de Grey, PhD, Sens Foundation

 Jeanne F. Loring, PhD, The Scripps Research Institute

 Henry McCusker, Scimitar Equity

 Graham Parker, PhD, Wayne State University School of Medicine

11:00a - 12:30a  -Conference Room 1-2

Panel Discussion

Innovation Showcase

Tools of the Trade: Crucial Technologies for the Core Lab (supported by Bioscience Technology)

Moderator

 Tim Studt, Advantage Media Group

Speakers

 Sunita D'Souza, PhD, Mount Sinai School of Medicine

 Tenneille Ludwig, PhD, WiCell

 Ian McNiece, PhD, MD Anderson Cancer Center

 Mark Tomishima, PhD, Memorial Sloan-Kettering Cancer Center

11:00a - 12:30p  -Conference Room 3-4

Panel Discussion

Reg Med Capital Conference

Company Presentations – Session 1

Moderator

 Robert E. Margolin, MBS, MBA, Cognate BioServices, Inc.

Speakers

 Craig Carlson, Stemedica USA

 Kenneth L. Harris, Cesca Therapeutics

 Michael McCullough, MD, RegenMed Systems

 Michael D. West, PhD, BioTime, Inc.

 Robert Wynalek, DiscGenics

11:00a - 12:30p  -Conference Room 13-14

Panel Discussion

Discovery

Exciting Discoveries in Pluripotency and Differentiation

Moderator

 Don L. Gibbons, California Institute forr Regenerative Medicine

Speakers

 Tiziano Barberi, PhD, Texas Biomedical Research Institute

 Norio Nakatsuji, DSc, Institute for Integrated Cell-Material Science (iCeMS), Kyoto University

 Thomas P. Zwaka, MD, PhD, Icahn School of Medicine at Mount Sinai

12:30p - 2:30p  -Salon G-M

Conversations with Experts – Lunch

2:30p - 3:30p  -Salon A-B

Concurrent Session

Innovation Showcase

Creative Ways to Organize, Finance & Launch Manufacturing Initiatives (Sponsored by Stemedica, Inc.)

The “Creative Ways To Organize, Finance & Launch Manufacturing Initiatives” session will explore the innovative aspects of how technology, financing and collaboration are rapidly changing the strategies and approaches to manufacturing in our space.  These innovative manufacturing approaches are beginning to equip our industry with the necessary expertise, resources and infrastructure to produce cellular products at scale while maintaining potency, consistency and safety profiles. The ultimate result will be a more cost effective method to bring cellular therapies to market with a higher clinical trial to commercialization success ratio. The renowned panelists will share their experience and perspective on the current state of manufacturing as well as provide insight on the future in a dynamic and collaborative panel discussion. 

Moderator

 David M. McGuigan, Stemedica, Inc.

Speakers

 Steven Lynum, Panasonic Healthcare Corporation

 Chris Mason, MBBS, PhD, FRCS, University College London

 Gerald W. Parker, DVM, PhD, MS, Texas A&M Health Science Center

2:30p - 3:30p  -Salon C-D

Concurrent Session

Translation & Clinical Trials

Stem Cells Translation: From the Bench to the Clinic- Supported by AlphaMed Press

The Session Objectives are to detail the progress and future aspirations for translating stem cell therapies to the clinic.  Having adequate translation requires the development of infrastructure, resources, and technology to efficiently run clinical trials, evaluate safety and efficacy for new therapies, and develop a process to ensure rapid regulatory approval for new therapies with regulatory agencies. This should also enable commercialization of medical devices, reagents, and other products required for cell therapies through the development and dissemination of innovative methods and procedures for regenerative medicine based products.  A panel of experts will discuss these important topics in an interactive format.

Moderator

 Anthony Atala, MD, Wake Forest University Medical Center

Speakers

 Rick Blume, Excel Venture Management

 Geoff Crouse, MBA, MPH, Cord Blood Registry

 C. Randal Mills, PhD, California Institute for Regenerative Medicine (CIRM)

2:30p - 3:30p  -Conference Room 1-2

Concurrent Session

Discovery

Using Stem Cells and Other Advanced Therapies to Tame Cancer

Speakers

 William K. Decker, PhD, Baylor College of Medicine

 LuZhe Sun, PhD, University of Texas Health Science Center at San Antonio

 Avi Treves, PhD, Sheba Medical Center

2:30 - 3:30  -Conference Room 3-4

Concurrent Session

Reg Med Capital Conference

Protecting Your Intellectual Property: The Foundation to Raising Capital

While patents form the core asset of most firms in the life science field, in †he past few years they’ve been scrutinized by the government and the US Supreme Court.  The panel will look at the current US patent landscape including recent life science patent decisions by the US Supreme Court with an emphasis on their impact in the stem cell field. The panel will also consider what’s presently patentable in the stem cell field in the US and in Europe and look at some tools for evaluating stem cell patent portfolios.”

Moderator

 S. Peter Ludwig, Fish & Richardson, P.C.

Speakers

 S. Peter Ludwig, Fish & Richardson P.C.

 Robin A. Chadwick, Ph.D., J.D., Schwegman Lundberg Woessner P.A.

 Maria Luisa Palmese, Kenyon & Kenyon LLP

 Robert C. Sullivan, Jr., Fish & Richardson P.C.

2:30p - 3:30p  -Conference Room 13-14

Concurrent Session

Regenerative Services & Restorative Medicine

Plastic Surgery and the Clinical Use of Stem Cells

Moderator

 Ricardo Luis Rodriguez, MD, Cosmeticsurg

Speakers

 Michael R. Davis, MD, FACS, United States Army Institute of Surgical Research

 Jaime R. Garza, MD, DDS, FACS, University of Texas Health Science Center at San Antonio

 Jeffrey R. Janus, MD, Mayo Clinic

 J. Peter Rubin, MD, University of Pittsburgh

2:30p - 3:30p  -Conference Room 17-18

Concurrent Session

Hot Topics & Future Trends

Regenerative Medicine and Stem Cell Institutes: The Best Practices for Achieving Success

Moderator

 Jonathan Thomas, PhD, JD, California Institute for Regenerative Medicine

Speakers

 Jan A. Nolta, PhD, Professor, Stem Cell Program and Institute for Regenerative Cures, UC Davis

 Brock C. Reeve, Harvard Stem Cell Institute, Polliwog Regenerative Medicine Fund

 Andre Terzic, MD, PhD, Center for Regenerative Medicine, Mayo Clinic

3:30p - 4:00p  -Salon G-M

Break

Afternoon Break – Exhibits Open

4:00p - 5:00p  -Salon A-B

Concurrent Session

Regenerative Services & Restorative Medicine

Clinicians Guide to Avoiding Compliance Issues with the FDA and FTC

Moderator

 R. Lee Buckler, BEd, LLB

Speaker

 Randy J. Prebula, Hogan Lovells US LLP

 Shane A. Shapiro, MD, RMSK, Mayo Clinic College of Medicine

4:00p - 5:00p  -Salon C-D

Track Keynote

Hot Topics & Future Trends

Regenerative Medicine for Aging: Making Rejuvenation Comprehensive, not Cosmetic

Regenerative medicine as convemtionally defined consists, essentially, of cell-based and organ-based therapies: stem cells and tissue engineering. The versatility of these approaches is becoming more and more evident. However, as I will discuss, there are several major aspects of aging that are probably not – or only partially – amenable to repair (i.e. rejuvenation) by these methods. I will present a range of other technologies – ones not usually classified as regenerative medicine, though perhaps they should be – that I claim will be vital counterparts to stem cells and tissue engineering, dovetailing with them to jointly deliver truly comprehensive restoration of the molecular and cellular structure of the aging boy to broadly how it was in early adulthood.

Presenter

 Aubrey de Grey, PhD, SENS Foundation

4:00p - 5:00p  -Conference Room 1-2

Concurrent Session

Innovation Showcase

Biobanking Challenges and Strategies for Developing Cell-based Biologics Towards Clinical and Commercialization (supported by Fisher BioServices)

Moderator

 Dan O'Donnell, Fisher BioServices

Speakers

 Ian McNiece, PhD, MD Anderson Cancer Center

 Mary Pat Moyer, PhD, INCELL Corporation

4:00p - 5:00p  -Conference Room 3-4

Concurrent Session

Reg Med Capital Conference

State of the Public Markets for RegMed Companies

Moderator

 S. Peter Ludwig, Fish & Richardson, P.C.

Speakers

 S. Peter Ludwig, Fish & Richardson P.C.

 Henry McCusker, Scimitar Equity

 Michael D. West, PhD, BioTime, Inc.

4:00p - 5:00p  -Conference Room 13-14

Concurrent Session

Translation & Clinical Trials

Innovative Clinical Trials: Academic Institutions

The field of Regenerative Medicine has seen exponential growth in the number of clinical trials over the last decade with a high percentage occurring in academic institutions. Cellular therapy is the most advanced area in Regenerative Medicine but we are also seeing emergence of tissue engineered products in clinical research as observational studies or early phase clinical trials. The presentation will introduce clinical trials/studies as they occur in academic institutions reviewing some examples of tissue engineered products. Discussion will focus on the technology, expertise required, regulatory considerations and other challenges in clinical translation.

Moderator

 Julie G. Allickson, PhD, Wake Forest Institute for Regenerative Medicine

Speakers

 Julie G. Allickson, PhD, Wake Forest Institute for Regenerative Medicine

 Atta Behfar, MD, PhD, Mayo Clinic

 Joshua M. Hare, MD, FACC, FAHA, University of Miami School of Medicine

4:00p - 5:00p  -Conference Room 17-18

Concurrent Session

Discovery

The Science of Perinatal Stem Cells: Cord Blood, Placental Cells and Wharton’s Jelly

Moderator

 Rasul Chaudhry, PhD, Oakland University

Speakers

 Stewart E. Abbot, PhD, Celgene Cellular Therapeutics

 Kyle J. Cetrulo, AuxoCell Laboratories, Inc.

 Raphael Gorodetsky, PhD, Hadassah Medical Center

5:00p - 6:30p  -Salon G-M

Exhibits / Posters Reception

Exhibitor Networking Reception & Poster Viewing with Presenters Present

Poster Presenters will be present to share about their posters, and judges will review at this time.

6:30p - 7:30p  -Salon E Foyer

Reception

Stem Cell Action Awards Pre-Dinner Reception (Sponsored by Cord Blood Registry)

A ticket is required to attend this event.  Tickets for this reception and the Stem Cell Action Awards are available for $125.00 per person.  They can be purchased online through our registration system, or onsite at the conference at the Registration Desk, up to 12:00 noon on Wednesday, December 3, 2014.

7:30p - 9:30p  -Salon E-F

Stem Cell Action Awards Gala Dinner

A ticket is required to attend this event.  Tickets are $125.00 per person, and can be purchased
on line through our reservation system, or at the Registration Desk on site at the conference by NOON on Wednesday, December 3, 2014.

Thursday, December 4, 2014

7:15a - 7:00p  -Registration 2

Attendee Registration

7:15a - 8:15a  -Salon G-M

Networking Breakfast

8:15a - 8:30a  -Salon E-F

Opening Remarks – Special Announcement from Conquer Paralysis Now

Moderator

 Bernard F. Siegel, JD, Genetics Policy Institute

Speaker

 Ida Cahill, Conquer Paralysis Now

 Sheryl Sculley, City of San Antonio

8:30a - 9:00a  -Salon E-F

Plenary Keynote

The Expanding Universe of CRISPR and Gene Editing

Presenter

 George M. Church, PhD, Harvard Medical School and MIT Health Sciences and Technology

9:00a - 10:00a  -Salon E-F

Track Keynote

Regenerative Services & Restorative Medicine

Fat Grafts: From a Challenging Past to an Innovative Present, and into a Revolutionary Future

Presenter

 Sydney R. Coleman, MD, Tribeca Plastic Surgery

9:00a - 10:00a  -Salon A-B

Panel Discussion

Discovery

Utilizing Stem Cells in the Effective Treatment of Heart Disease

Moderator

 John P. Cooke, MD, PhD, Houston Methodist Research Institute

Speakers

 Atta Behfar, MD, PhD, Mayo Clinic

 Karl-Henrik Grinnemo, MD, Karolinska Institutet

 Joshua M. Hare, MD, FACC, FAHA, University of Miami School of Medicine

9:00a - 10:00a  -Salon C-D

Panel Discussion

Translation & Clinical Trials

Global Strategies – Finding Common Ground

Moderator

 Michael N. Druckman, Hogan Lovells US LLP

Speakers

 Chris Mason, MBBS, PhD, FRCS, University College London

 Michael H. May, PhD, Centre for Commercialization of Regenerative Medicine (CCRM)

 Avi Treves, PhD, Sheba Medical Center

9:00a - 10:00a  -Conference Room 1-2

Concurrent Session

Innovation Showcase

BioFabrication: Advanced Manufacturing Technologies for Tissue Engineering

Moderator

 Joo L. Ong, PhD, The University of Texas at San Antonio (UTSA)

Speakers

 Julie G. Allickson, PhD, Wake Forest Institute for Regenerative Medicine

 Teja Guda, PhD, University of Texas at San Antonio

 Jian Ling, PhD, Southwest Research Institute

9:00a - 10:00a  -Conference Room 3-4

Concurrent Session

Reg Med Capital Conference

Company Presentations – Session 2

Moderator

 Connie Harrell, Keiretsu Forum

Speakers

 R. Lee Buckler BEd, LLB, RepliCel Life Sciences, Inc.

 Dr. Ross A. MacDonald, Cynata Therapeutics, Ltd.

 Dale Tomrdle, The GID Group, Inc.

9:00a - 10:00a  -Conference Room 17-18

Panel Discussion

Hot Topics & Future Trends

Building a Regional Innovation Ecosystem to Foster Regenerative Medicine and Life Science Companies

Building a Regional Innovation Ecosystem to Foster the Growth of Regenerative Medicine and Other Life Science Companies

Creative biomedical research does not arise in an intellectual vacuum, nor do innovative discoveries with very promising commercial potential automatically result in new products or services. There needs to be an “innovation ecosystem” that drives discovery and nurtures novel findings into the patient marketplace. First class research, sophisticated technology transfer personnel, experienced entrepreneurs, creation of incubator facilities, availability of capital, and supportive public agencies are just some of the elements that are required in an innovative environment. This panel will define and describe such an ecosystem in San Antonio which may serve as a model for other cities and regions around the country.

Moderator

 Kenneth P. Trevett, JD, Texas Biomedical Research Institute

Speakers

 Ed Davis, San Antonio Economic Development Corporation

 Randy Goldsmith, PhD, The Texas Technology Development Center

 John Kerr, Texas Next Capital

 Ann Stevens, BioMed SA

10:00a - 10:30a  -Salon G-M

Break

Morning Break – Exhibits Open

10:30a - 12:00p  -Salon E-F

Concurrent Session

Discovery

The Science of Gene Editing

Science of Gene Editing

The last five years have brought a wealth of new technologies for modification of stem cells, from new methods to reprogram stem cells, forward differentiate stem cells, select for pure populations of differentiated stem cells and create genetic modifications in stem cells. This panel will be discussing some of the newer genetic modification techniques, including piggyBac, TALEN, CRIPSR, NextGEN CRISPR and Footprint-Free Gene Editing. Practical applications and implications for both basic research and translational medicine will be contemplated and discussed with the panel participants and audience.

Moderator

 Eric Ostertag, MD, PhD, Transposagen

Speakers

 George M. Church, PhD, Harvard Medical School and MIT Health Sciences & Technology

 Hiromitsu Nakauchi, MD, PhD, Stanford University and University of Tokyo

10:30a - 12:00p  -Salon A-B

Concurrent Session

Hot Topics & Future Trends

Reproducibility and Rigor in Research: What We have Learned from STAP Debacle

The panel members’ roles as a ‘PI’, an ‘Editor’, and a ‘Public Advocate’ will serve as a basis for discussing the ethics of publication in regenerative medicine and in particular when the interpretation and acceptance of that work is called into question. Landmark examples will be used to kick off the discussion concerning the responsibilities of the laboratories, editors and the scientific community, but the panel also anticipates a lively, constructive discussion with the audience.

Moderator

 Graham Parker, PhD, Wayne State University School of Medicine

Speakers

 Jeanne F. Loring, PhD, The Scripps Research Institute

 Ivan Oransky, MD, MedPage Today, Retraction Watch

10:30a - 12:00p  -Salon C-D

Concurrent Session

Translation & Clinical Trials

Banking on Cord Blood Stem Cells: Is the Future Here? (supported by Cord Blood Registry)

Panel discussion will provide updated information regarding preclinical and clinical experience with autologous stem cells for neurological applications and other potential future uses. Learning objectives to include:

  • To analyze the potential role of cord blood stem cells as a promising therapeutic tool in the development of innovative treatments
  • To explain the current usage and therapeutic potential of cord blood stem cells
  • To describe the use of autologous cord blood stem cells in clinical regenerative medicine applications
  • To review approaches for reprogramming cord blood cells into induced pluripotent stem cells and potential applications in regenerative medicine.

Moderator

 Heather Brown, MS, LCGC, Cord Blood Registry

Speakers

 Charles S. Cox, MD, UT Health Science Center at Houston

 Mahendra Rao, MD, PhD, Q Therapeutics & NYSCF

 Frances Verter, PhD, Parents Guide to Cord Blood Foundation

10:30a - 12:00p  -Conference Room 1-2

Concurrent Session

Innovation Showcase

Selecting the Right CRO/CMO Partner (supported by Bioscience Technology)

Moderator

 Christina Jakubowski, Bioservices Tehchnology

Speakers

 R. Lee Buckler BEd, LLB, RepliCel Life Sciences, Inc.

 Robert E. Margolin, MBS, MBA, Cognate BioServices, Inc.

 Mary Pat Moyer, PhD, INCELL Corporation

10:30a - 12:00p  -Conference Room 3-4

Concurrent Session

Reg Med Capital Conference

Company Presentations – Session 3

Moderator

 Connie Koch Harrell, Keiretsu Forum Southern CA, LLA

Speakers

 Cristina Correai, Stemmatters

 Bob Hutchens, StemBioSys, Inc.

 Daniel R. Lee, Aperion Biologics, Inc.

 Gary Sams, PhD, Progenitor Life Sciences, LLC

 Chikafumi Yokoyama, PhD, ReproCELL, Inc.

10:30a - 12:00p  -Conference Room 13-14

Concurrent Session

Regenerative Services & Restorative Medicine

Cell Standardization for Clinical Practice (supported by AABB)

Moderator

 Uplaksh Kumar, PhD, AABB

Speakers

 Jim Beltzer, PhD, Terumo BCT

 James Lovgren, ORIG3N

 Madhusudan V. Peshwa, PhD, MaxCyte, Inc.

12:00p-1:30p  -Salon E Foyer

Pre-Paid Box Lunch Pick-Up

You may order a boxed lunch in ADVANCE of the conference for $20.00.
This can be done through the registration system.   A limited number may be
available for payment onsite.

12:10p - 1:30p  -Salon E-F

Symposia

Navigating the Two Valleys of Death: Transforming Scientific Advances into Medical Breakthroughs (Symposium sponsored by BioBridge Global

From a societal return perspective, the ultimate payoff from investments into basic biomedical research comes in the form of the medical breakthroughs enabled by it. It would be unrealistic to expect all basic biomedical research to yield inventions with industrial applicability. Nonetheless, most breakthroughs in our understanding of the molecular cell biology basis of human disease eventually find their way to patients in the form of medical interventions (drugs, biologics, medical devices, cell therapies and/or procedures) physicians can prescribe on behalf of a patient in need. Sean Thompson begins this session by providing an overview of the reality of “bench to bedside”. He explains how the tangible results of basic biomedical research move along the biomedical product development pathway, introduces the notion of the “two valleys of death” that exist along this pathway, and suggests how blood and tissue centers and other non-profits may help overcome these two obstacles to successful biomedical product development. The following subject matter expert presenters in the session will address discrete segments of the product development pathway. Marie Csete from the Huntington Medical Research Institutes will provide the perspective of a center where scientific advances/discoveries are first made, and suggest ways to optimize the translation of scientific advancements to medical breakthroughs. Next, Steve Schmid from Vivo Biosciences will discuss the importance of providing proof-of-concept data sufficient to encourage startup investors and later existing biomedical companies to in-license biomedical technologies and invest the resources required to transform the technology into marketable product. Next, Randy Goldsmith will address the non-technology aspects of biomedical opportunities and discuss the importance of presenting an Investor-Ready investment opportunity by showing how a given product opportunity can be transformed into thriving business. Finally, John Kerr of TexasNext Capital will speak from the perspective of a private equity/venture capital investor tasked with carefully choosing companies in which to invest fund resources to earn an appropriate risk-adjusted return for investors.

Moderator

 Sean Thompson, MS, MBA, CLP, BioBridge Global

Speakers

 Marie Csete, MD, PhD, Huntington Medical Research Institute

 Randy Goldsmith, PhD, The Texas Technology Development Center

 John Kerr, Texas Next Capital

 Steven M. Schmid, PhD, Vivo Biosciences

12:10p - 1:30p  -Salon A-B

Symposia

Japan Symposium: Mass Culture System, QC, 3D Construction, Freezing System and Delivery System

Moderator

 Takashi Asada, PhD, Kyoto University

Speakers

 Tomoki Aoyama MD, PhD, Kyoto University

 Kouichi Hasegawa, PhD, Kyoto University

 Masanari Kitagawa, PhD, Takara Bio Inc.

 Koji Kuchiishi, Cyfuse Biomedical K.K.

 Mikiyoshi Nakamichi, Tamai-Kasei. K.K.

 Norio Nakatsuji, DSc, Institute for Integrated Cell-Material Science (iCeMS), Kyoto University

 Taito Nishino, Nissan Chemical Industries, Ltd.

 Yasuhiro Suzue, Kaneka Corporation

 Tomomi Yamazaki, NEDO

 Chikafumi Yokoyama, PhD, ReproCELL, Inc.

12:10p - 1:30p  -Salon C-D

Workshop

7th Annual IRB, ESCRO and SCRO Workshop – Meeting the Institutional Oversight Challenges to Stem Cell Research

This year’s Workshop will focus on how institutional oversight of stem cell research has evolved in response to the many advances in stem cell science and in light of the absence of overriding federal regulation and the diversity of state requirements.
The session will include:
·        A brief review of how funding requirements, voluntary professional guidance, state-based initiatives, and human subject regulations are shaping policies and procedures for stem cell research oversight.
·        Case studies that illustrate how the nature of research undertaken and the differences in the regulations, funding requirements and local attitudes have shaped the role of IRB/ESCRO/SCROs in different jurisdictions.
·        Interactive discussion driven by participants and guided by case questions.  Bring your questions and burning issues!

Speakers

 Melinda Abelman, MSc, CIP, Partners HealthCare System

 Amy Wilkerson, The Rockefeller University

1:30p - 2:30p  -Salon E-F

Concurrent Session

Discovery

Stem Cells for Disease Modeling

  • Disease-modeling: technology development and use
    –Disease-specific stem cells: progress
    –Disease-specific stem cells: hurdles
    –Attrition rate indicators
  • Disease-modeling: case studies
    –Applications in cardiovascular diseases
    –Applications in diabetes and its complications
    –Applications in neurologicaldisorders
  • Deployment of stem cells for research: Pharma & CROs
    –Toxicological applications: cardiomyocytes and QT interval
    –Trends in strategic alliances
    –CRO services as a proxy for technology maturity; cost considerations

Moderator

 Alain Vertes, PhD, NxR Biotechnologies

Speakers

 Timothy J. Nelson, MD, PhD, Mayo Clinic

 Fernando Pitossi, PhD, Leloir Institute

 Gary D. Smith, PhD, HCLD, University of Michigan

1:30p - 2:30p  -Salon A-B

Concurrent Session

Regenerative Services & Restorative Medicine

RegMed Solutions for Orthopedic Injuries and Extremity Regeneration

Moderator

 William L. Murphy, PhD, University of Wisconsin

Speaker

 Chris Rathbone, PhD, United States Army Institute of Surgical Research

 Dmitry Tuder, MD, San Antonio Military Medical Center

1:30p - 2:30p  -Salon C-D

Concurrent Session

Translation & Clinical Trials

Public Policy and Ethics – Challenges and Solutions

Moderator

 Alan Jakimo, JD, Sidley-Austin, LLP

Speakers

 Timo Faltus, Translational Centre for Regenerative Medicine (TRM)

 Jeanne F. Loring, PhD, The Scripps Research Institute

 Kirstin R.W. Matthews, PhD, Rice University

 Beth Roxland, JD, M.Bioethics, Johnson & Johnson, Inc.

1:30p - 2:30p  -Conference Room 1-2

Concurrent Session

Innovation Showcase

Storage Technology Trends (supported by Bioscience Technology)

Moderator

 Christina Jakubowski, Bioscience Technology

Speakers

 Michael Marciniak, Panasonic Healthcare Corporation of North America

 Michael C. Hiles, PhD, Cook Biotechnology Inc.

1:30p - 2:30p  -Conference Room 3-4

Panel Discussion

Reg Med Capital Conference

Innovative Ways to Fund Innovative Companies: Power to the People – supported by Polliwog Regenerative Medicine Fund

Moderator

 Brock C. Reeve, PhD, Polliwog Regenerative Medicine Fund

Speakers

 Kurt H. Kruger, WR Hambrect + Co.

 Dan Gincel, PhD, MD Stem Cell Research Fund

 Michael H. May, PhD, Centre for Commercialization of Regenerative Medicine (CCRM)

 Brock C. Reeve, Harvard Stem Cell Institute, Polliwog Regenerative Medicine Fund

1:30p - 2:30p  -Conference Room 17-18

Concurrent Session

Hot Topics & Future Trends

Eureka! Now What? (supported by Hogan Lovells)

You’ve made the discovery and identified clinical applications, but now what?  It’s time to take the technology out of the lab.  This Post-Discovery 101 session is designed to provide overview and insight into such areas as technology transfer options and the basics of FDA regulation and terminology.  Come gain insight on the steps to commercialization and branding with this practical and informative global view of a critical area of innovation development.

Moderator

 Michael Druckman, Hogan Lovells, US, LLP

Speakers

 Jerry Phillips, RPh, Drug Safety Institute, inc.

 Maria A. Vodicka, PhD, Hogan Lovells

2:30p - 3:30p  -Salon E-F

Track Keynote

Translation & Clinical Trials

IPSC’s for Drug Discovery

Presenter

 Mahendra Rao, PhD, Q Therapeutics and The New York Stem Cell Foundation

2:30p - 3:30p  -Salon A-B

Concurrent Session

Regenerative Services & Restorative Medicine

Wound Healing and Restorative Medicine

Moderator

 Michael R. Davis, MD, FACS, US Army Institute of Surgical Research

Speaker

 Rodney Chan, MD, FACS, FRSCS, San Antonio Military Medical Center and Uniformed Services University of the Health Sciences

 Robert J. Christy, PhD, US Army Institute of Surgical Research

2:30p - 3:30p  -Salon C-D

Concurrent Session

Hot Topics & Future Trends

Growing Whole Organs

Moderator

 Tyler Emerson, New Organ

Speakers

 Julie G. Allickson, PhD, Wake Forest Institute for Regenerative Medicine

 Hiromitsu Nakauchi, MD, PhD, Stanford University and University of Tokyo

 Doris A. Taylor, PhD, FAHA, FACC, Texas Heart Institute at St. Luke's Episcopal Hospital

2:30p - 3:30p  -Conference Room 1-2

Concurrent Session

Innovation Showcase

Cell Culture: Finding the Right Formulas for Your Laboratory

Moderator

 Mary Pat Moyer, PhD, InCell Corporation LLC

Speakers

 Taito Nishino, Nissan Chemical Industries, Ltd.

 Rae D. Record Ritchie, PhD, Cook Biotech, Inc.

 Martha S. Rook, PhD, EMD Millipore Corporation

2:30p - 3:30p  -Conference Room 3-4

Concurrent Session

Reg Med Capital Conference

Future Trends: Presented by Leading Investment Banks

Moderator

 Alan Jakimo, JD, Sidley Austin LLP

Speaker

 Michael Meyers, MPH, T.R. Winston & Company

 Connie Koch Harrell, Keiretsu Forum Southern California, LLA

2:30p - 3:30p  -Conference Room 13-14

Concurrent Session

Discovery

Pivotal Research to Understand and Overcome Disease

Moderator

 Graham Parker, PhD, Mary Ann Liebert, Inc.

Speakers

 Matthias Corbascio, MD, PhD, Karolinska University Hospital, Solna

 Paula K. Shireman, MD, University of Texas Health Science Center San Antonio South Texas Veterans Health Care System

 Yoshimi Yashiro, PhD, Kyoto University

3:30p - 4:00p  -Salon G-M

Afternoon Break – Exhibits Open

4:00p - 5:00p  -Salon E-F

Panel Discussion

Huntington’s Disease: Unlocking the Mystery and Finding a Cure

The session “Huntington’s disease: Unlocking the Mystery and Finding a Cure” features four speakers committed to developing stem cell therapies to help families affected by Huntington’s disease (HD) and Juvenile Huntington’s disease (JHD). HD and JHD are devastating neurodegenerative disorders caused by a mutation in the Huntingtin (HTT) gene which passes from one generation to the next. The mutation which causes HD was identified in 1993 as an expansion of a triplet repeat section on one copy of the HTT gene. Huntington’s disease is dominantly inherited, which means that each of an affected person’s children has a 50% risk of inheriting the mutant gene. JHD has an early onset, more complex symptoms, and is particularly heartbreaking when it affects children. Unfortunately, no disease-modifying treatments currently exist to help HD patients.

Dr. Randy Mills is the president of the California state stem cell funding agency, the California Institute for Regenerative Medicine (CIRM). He will discuss his agency’s support for developing therapies for HD and other devastating disorders. Dr. Jan Nolta, Director of the Stem Cell Program at the University of California Davis, will discuss therapeutic approaches in development for HD and JHD at UC Davis. Dr. Vicki Wheelock is director of the HDSA Center of Excellence at the UC Davis She is the Principal Investigator and Dr. Nolta is the co-Principal Investigator for a CIRM Disease Team Grant designed to obtain FDA approval to conduct a Phase 1 trial to assess the safety and tolerability of an adult stem cell/gene therapy candidate in HD patients. Dr. Wheelock will discuss PRE-CELL (ClinicalTrials.gov study identifier NCT01937923), the lead-in observational study of potential candidates for the planned future stem cell gene therapy trial HD-CELL, Katie Jackson, author and HD patient advocate, will discuss the hope that research and clinical trials bring to her family and others who are affected by HD.

For the first time, GPI is awarding a Stem Cell Action Award to a grassroots network of groups and individuals including Katie; the Inspiration Award will be presented to the Huntington’s disease Advocacy Community at the Stem Cell Action Awards Dinner.

Moderator

 Jan A. Nolta, PhD, University of California, Davis

Speakers

 Katie Jackson, Help 4 HD International, Inc.

 C. Randal Mills, PhD, California Institute for Regenerative Medicine (CIRM)

 Vicki L. Wheelock, MD, University of California, Davis

5:00p - 7:00p  -Salon G-M

Exhibits / Posters Reception

Exhibitor Networking Reception & Poster Viewing with Presenters Present

Poster Presenters will be present to share about their posters, and judges will review at this time.

5:30p - 7:00p  -Salon C-D

Symposia

Terumo BCT “Hands-On” Workshop & Presentation: Requirements for a Cell Therapy Facility: Expect the Unexpected

In this presentation, Patrick Hanley, PhD, Children’s National Medical Center, will walk attendees through the expected challenges associated with developing a cell therapy facility, including the facility itself, staff, costs, quality management and timing. In addition, the presentation will explore the many unexpected obstacles associated with cell therapy facilities, including the need for regulatory staff, space to store excessive documentation, the translation of research products into the clinic and much more. Following the presentation, Jim Beltzer, Terumo BCT, will provide an overview of the Quantum Cell Expansion, before breaking the group into four, hands-on educational sessions to explore the device’s capabilities in the areas of immunotherapy, gene therapy and cell therapy.

Speakers

 Jim Beltzer, PhD, Terumo BCT

 Patrick J. Hanley, PhD, Children's National and George Washington University

6:00p - 8:00p  -

Symposia

Scientific and Social Workshop during World Stem Cell Summit — Genome to Proteome at Single-Cell Resolution – Sponsored by Fluidigm

Offsite event to be held at: 

Biga on the Banks
203 South St. Mary’s St.
San Antonio, TX 78205

A short stroll down the Riverwalk or optional trolley transportation departing from the Marriott Rivercenter starting at 5:30.

Speakers

 Brian P. Hermann, PhD, University of Texas at San Antonio

 David Knapp, British Columbia Cancer Agency

 Ryan L. McCarthy, PhD, The University of Texas MD Anderson Cancer Center

7:00 p - 8:30p  -Sazo’s

Reception

REGMED CAPITAL CONFERENCE RECEPTION- for accredited investors, RMCC Presenters & Sponsors and San Antonio Host Committee (Sponsored by Keiretsu Forum and Targeted Technology Fund)

Invitation Only

Friday, December 5, 2014

8:00a - 1:00p  -Registration 2

Attendee Registration

8:00a - 9:00a  -Salon G-M

Networking Breakfast

8:00a - 2:00p  -Salon G-M

Exhibits Open

8:30a - 9:00a  -Salon E-F

Announcement of Poster Awards

 Bernard Siegel, JD, Genetics Policy Institute

 Alan Jakimo, JD, Sidley Austin, LLP

 David M. McGuigan, Stemedica Cell Technologies, Inc.

9:00a - 9:40a  -Salon E-F

Plenary Keynote

Human Eggs in Stem Cell Research and Reproduction

Presenter

 Dieter Egli, New York Stem Cell Foundation

9:00a - 10:00a  -Conference Room 3-4

Plenary Keynote

Reg Med Capital Conference

The Future of Regenerative Medicine and How to Finance it

Presenter

 Howard Leonhardt, Leonhardt Ventures

9:40a - 10:00a  -Salon E-F

Plenary Keynote

Development of Japanese Regenerative Medicine Industry

Presenter

 Takuya Yokokawa, FujiFilm

10:00a - 11:00a  -Salon E-F

Panel Discussion

Translation & Clinical Trials

Cardiovascular Clinical Trials

Moderator

 Darcy L. DiFede, University of Miami

Speakers

 John P. Cooke, MD, PhD, Houston Methodist Research Institute

 James T. Willerson, MD, The University of Texas Health Science Center, Houston

10:00a - 11:00a  -Salon A-B

Panel Discussion

Discovery

NEUROLOGICAL SOLUTIONS FOR CHRONIC MEDICAL CONDITIONS

Moderator

 Marcel M. Daadi, PhD, Texas Biomedical Research Institute

Speakers

 Erzsebet Kokovay, PhD, University of Texas Health Science Center at San Antonio

 Jeanne F. Loring, PhD, The Scripps Research Institute

 Evan Y. Snyder, MD, PhD, FAAP, Sanford-Burnham Medical Research Institute, Stem Cell Research Center

10:00a - 11:00a  -Salon C-D

Panel Discussion

Innovation Showcase

Data Analysis Needs in Regenerative Medicine (supported by Bioscience Technology)

Moderator

 Tim Studt, Advantage Media

Speakers

 Michele Reilly, Turing, Inc.

 Michael Vassar, MetaMed

 James M. Watt, PhD, Eagle Medical Services, LLC

10:00a - 11:00a  -Conference Room 3-4

Panel Discussion

Reg Med Capital Conference

Company Presentations – Session 4

Speaker

 Wei "William" Cao, PhD, BM, Cellular Biomedicine Group

 Jack Crawford, MS, Hera Testing Laboratories, Inc.

 Claudia Zylberberg, PhD, Akron Biotechnology, LLC

 Jun Wang, PhD, Phycin, LLC

10:00a - 11:00a  -Conference Room 13-14

Panel Discussion

Regenerative Services & Restorative Medicine

Stem Cell Treatments in Sports Medicine

Speakers

 Paul S. Saenz, DO, Sports Medicine Associates

 Shane A. Shapiro, MD, RMSK, Mayo Clinic College of Medicine

10:00a - 11:00a  -Conference Room 17-18

Panel Discussion

Hot Topics & Future Trends

Academic and Commercial Opportunities in Pursuit of Longevity

Despite the incessant media distractions that describe it as a “quest for immortality” or the like, medical research to postpone the ill-health of old age is just that: medical research, no more and no less, with a potential side-effect of extending longevity but without having that as its raison d’etre. In the past decade there has been a huge acceleration of progress in the enabling biomedical technologies required to deliver eventual, comprehensive medical control and elimination of age-related ill-health, with the result that not only academics but also the private sector has become involved in this space to a degree that would have been inconceivable not long ago. In this session we will survey a selection of these advances and their implications for future progress.

 

Moderator

 Aubrey de Grey, PhD, SENS Foundation

Speakers

 Rochelle Buffenstein, PhD, UTHSCSA

 Xiao-Dong Chen, MD, PhD, StemBioSys, Inc.

 Matthew Scholz, Immusoft Corporation

11:00a - 11:30a  -Salon G-M

Morning Break

11:30a - 12:30p  -Salon E-F

Concurrent Session

Translation & Clinical Trials

The Life of a Cellular Therapeutic from Conception to Maturity as Viewed through the Lenses of Academia, Regulatory and Commercialization. (Supported by the International Society for Cellular Therapy – ISCT)

Professor A. L. Kleehall at the High and Mighty Research Institute (HMRI) has been working on developing a more sensitive bio-assay for early stage cirrhosis of the liver. In one experiment, he has been placing cirrhotic mouse livers into tissue culture with different cell lines whose metabolism is sensitive to changes in liver enzymes, notably ALT. In one of his cultures, however, he notes that in the most cirrhotic livers the cirrhosis appears to be reversing. At first he believes that he must have just mixed up the cultures, but after several repeat experiments, he notes that the particular cell line, Delta Tau Chi, seems to be interacting with the livers. On a whim, Prof. Kleehall has a pathologist friend make thin sections of the repairing livers and stain them. On microscopic examination, it is clear that Delta Tau Chi cells are invasively migrating to the areas of scar tissue. The potential of such a cell line to treat a range of patients from hepatitis C afflicted to recovered alcoholics is not lost on Prof. Kleehall, and he would like to get his new discovery into clinical application as soon as possible. In this presentation, four of Prof. Kleehall’s friends who are all active in the International Society for Cellular Therapy will describe how they bring the elements of academic strength, regulatory know-how, and a strong commercial involvement to help Prof. Kleehall bring his discovery to maturity as a therapeutic agent.

Moderator

 William E. Janssen, PhD, International Society for Cellular Therapies (ISCT)

Speakers

 Massimo Dominici, MD, International Society of Cellular Therapies (ISCT)

 Karen M. Nichols, Esq., Conkwest, Inc.

 Claudia Zylberberg, PhD, Akron Biotechnology, LLC

11:30a - 12:30p  -Salon A-B

Concurrent Session

Discovery

The Third Pillar of Pluripotency: Somatic Cell Nuclear Transfer

Moderator

 Mahendra Rao, MD, PhD, Q Therapeutics &The New York Stem Cell Foundation

Speakers

 Stephen M. W. Chang, PhD,Vice President, Research and Development, The New York Stem Cell Foundation

 Dieter Egli, PhD, New York Stem Cell Foundation Research Institute

 Aaron D. Levine, Georgia Tech

11:30a - 12:30p  -Conference Room 17-18

Concurrent Session

Hot Topics & Future Trends

New Paths to the Final Frontier: Enabling Stem Cell Research in Space for Life on Earth (Supported by CASIS)

New Paths to the Final Frontier:  Enabling Stem Cell Research in Space for Life on Earth
(Supported by CASIS)

 

The International Space Station U.S. National Lab is a new outpost on the frontier of medical discovery. In stem cell biology, the frontier is everywhere. This session will focus on the unique possibilities of stem cell research in modeled microgravity on Earth and in microgravity on the International Space Station (ISS). Microgravity, or weightlessness, induces a vast array of molecular changes in organisms encompassing bacteria to humans, including global alterations in gene expression, physiological response, and the three-dimensional aggregation of cells into tissue-like architecture. Experiments on Earth and in space have also shown that microgravity induces profound changes in the growth, proliferation and differentiation of stem cells. In addition, microgravity alters many observable phenomena that directly impact cellular physiology enabling studies seeking to accelerate stem cell therapy, drug discovery and pre-clinical screening studies using cell culture- and animal-based models. CASIS, the Center for the Advancement of Science in Space, was selected by NASA in 2011 to manage the ISS National Lab. As a non-profit organization, CASIS seeks to facilitate access and maximize use of this unparalleled platform for innovation to benefit humankind. In 2013, CASIS awarded grants to seven stem cell investigations for flight and ground research projects. Today, you will hear results from three of these researchers. Dr. Carl Gregory from Texas A&M Health Science Center, together with Drs. Roland Kaunas and Jun Kameoka from the Texas A&M Departments of Biomedical and Electrical & Computer Engineering, will describe his team’s work to develop a new system for co-culturing and analyzing stem cells mixed with bone tumor cells in microgravity. Dr. Mary Kearns-Jonker from the Loma Linda University School of Medicine will describe her research on the aging of neonatal and adult cardiac stem cells in microgravity with the ultimate goal of improving cardiac cell therapy. Dr. Abba Zubair of the Mayo Clinic will describe his use of the microgravity environment to grow stem cells that are of sufficient quality and quantity to use in the treatment of patients with stroke.

 

Moderator

 Michael S. Roberts, PhD, Center for the Advancement of Science in Space, Inc.

Speakers

 Carl Gregory, PhD, Texas A&M Institute for Regenerative Medicine

 Mary Kearns-Jonker, PhD, Loma Linda University School of Medicine

 Abba C. Zubair MD, PhD, Mayo Clinic Florida

12:30p - 2:00p  -Salon G-M

Pre-paid Box Lunch Pick-Up

You may order a boxed lunch in ADVANCE of the conference for $20.00.
This can be done through the registration system.   A limited number may be
available for payment onsite.

12:45p - 2:00p  -Salon E-F

Symposia

Bridging the Valleys of Death: How Blood Banks and Other Non-profits Can Help Advance the Field of Cell-Based Therapies/Regenerative Medicine (supported by BioBridge Global)

The translational pipeline is loaded with bumpy roads, valleys, and treacherous cliffs (and occasionally some smooth sailing). This session presents experts at various stages along that road, to discuss their experience in developing new lines of business in the regenerative medicine space, and their strategies for smooth progress through their developmental programs. The first two speakers come from the blood industry, the founding industry of cell therapies, though not yet in the mainstream of the new wave of stem cell and tissue engineering based therapies. Linda Myers will discuss how the South Texas Blood and Tissue Center developed a strategy to enter mainstream regenerative medicine via BioBridge Global. Lisa Shaffer will discuss the strengths blood centers generally bring to regenerative medicine research and clinical trials, and the efforts of a professional society to develop a rational entrance into new businesses for blood centers.   James Trager of Dendreon has seen the entire developmental pipeline of a dendritic cell therapy for prostate cancer, including many lessons for those in the process of developing cell-based therapies. Bruce Levine from Penn will present the academic perspective on the transition from discovery science in academics to the clinical trials stages with promising therapies for cancers, chimeric antigen receptor T cells. This panel promises both cautionary tales for all scientists in regenerative medicine, as well as models for inspired decision making in the development of a new industry.

Moderator

 Marie Csete, MD, PhD, Huntington Medical Research Institute

Speakers

 Bruce Levine, PhD, University of Pennsylvania

 Linda Myers, ASCP, MT, SBB, CQA (ASQ), BioBridge Global

 Lisa Shaffer, Blood Centers of Amerca (BCA)

 James B. Trager, PhD, Dendreon Corporation

2:00p - 3:00p  -Salon E-F

Concurrent Session

Translation & Clinical Trials

Stem Cell Registries and Banks: Advancing Regulation and Standardization

Moderator

 Rosario Isasi, MD, MPH, McGill University

Speakers

 Rosario Isasi, JD, MPH, McGill University and Genome Quebec Innovation Centre

 Andreas Kurtz, PhD, Charite Universitatsmedizin Berlin, Germany

 Tenneille Ludwig, PhD, WiCell

 Mahendra Rao, MD, PhD, Q Therapeutics & NYSCF

 Zachary Resch, PhD, Mayo Clinic

2:00p - 3:00p  -Salon A-B

Concurrent Session

Discovery

Stem Cells and Mental Health

 Session Content:  Chronic neurodegenerative diseases are some of the most complex and intractable to effectively treat.  Genetically modified rodents are no more models of Alzheimer disease (AD) than a plastic bag over the head is a model of respiratory distress.  It is no surprise that removal of imposed pathology restores health in rodents but not in humans, where the pathology reflects a complex etiology.  The promise of a cell model derived from patients with AD is supported by two decades of research showing that skin and blood cells from AD patients display fundamental abnormalities similar to those found in brain.  Disease-in-a-dish offers hope for the first experimental model to address the cellular basis of AD.  Analysis will offer opportunities to understand the systemic nature of AD and develop effective therapeutics.

Moderator

 George Perry, PhD, The University of Texas at San Antonio

Speakers

 Daniel J. Lodge, PhD, University of Texas Health Science Center

 Evan Y. Snyder, MD, PhD, FAAP, Sanford-Burnham Medical Research Institute, Stem Cell Research Center

2:00p - 3:00p  -Salon C-D

Concurrent Session

Hot Topics & Future Trends

NASA: Stem Cells in Space

The absence of gravity in space is a major concern for stem cell and tissue regenerative health during
long-term spaceflight.  Exposure to microgravity causes significant mechanical unloading, which results
in rapid alterations of mammalian physiology.  The last 50+ years of spaceflight in low Earth orbit have
shown immediate effects of microgravity exposure on loss of bone and muscles tissues, loss of
cardiovascular capacity, defects in wound and fracture healing, and reduced immune function.
Long periods of weightlessness may cause severe deficits in stem cell-based tissue regenerative health - 
a significant challenge for NASA to address in order to safely send astronauts on exploration-class
missions to Mars. To address the needs for stem cell and other cell science research on the International
Space Station (ISS) NASA has developed the new Bioculture System experimental platform that will
allow investigators to initiate and conduct on-orbit experiments. This cell culture capability, along with
advanced technologies for molecular biology and on-orbit measurement of gene expression, are now
coming online to bring the ISS National Laboratory one step closer to becoming a fully functional space
laboratory for advancing space biological sciences.

Moderator

 Jeffrey D. Smith, PhD, NASA Ames Research Center

Speakers

 Eduardo Almeida, PhD, NASA Ames Research Center

 S. Keith Chapes, PhD, MPH, Kansas State University

 David L. Tomko, PhD, NASA Headquarters

 David Wolf, MD, Former NASA Astronaut

2:00p - 3:00p  -Conference Room 3-4

Concurrent Session

Reg Med Capital Conference

Company Presentations – Session 6

Speakers

 Howard Leonhardt, Leonhardt Ventures

 Matthew Scholz, Immusoft Corporation

 Raj Singh, PhD, Vivo Biosciences

2:00p - 3:00p  -Conference Room 13-14

Concurrent Session

Regenerative Services & Restorative Medicine

Consumer Guide to Stem Cell Therapies: Questions to Ask Before Committing to Treatment

Speakers

 Steven A. Davis, MD, StemBioSys, Inc.

 Karen M. Nichols, Esq., Conkwest, Inc.

3:00p - 4:00p  -Salon E-F

Track Keynote

Regenerative Services & Restorative Medicine

Designing and Building Targeted Immunity from Patient’s Own Cells: Treating Untreatable Cancers or HIV

Presenter

 Bruce Levine, PhD, University of Pennsylvania

3:00p - 4:00p  -Salon A-B

Concurrent Session

Hot Topics & Future Trends

Effective Patient Advocacy — The Power of Commitment

Moderator

 Bernard F. Siegel, JD, Genetics Policy Institute

Speakers

 David L. Bales, Texans for Stem Cell Research

 Alan Fernandez, Genetics Policy Institute

 Tory Williams, AIM

3:00p - 4:00p  -Salon C-D

Concurrent Session

Translation & Clinical Trials

Establishing Best Practices for the Production of High Quality Stem Cell Lines (supported by Coriell)

With the availability of large numbers of human induced pluripotent stem cell (hiPSC) lines comes the need for the establishment of best practices governing derivation, growth, quality assessment, and cryopreservation. As hiPSC collections grow, biorepositories will play a critical role in defining these criteria to assure distribution of high-quality hiPSC lines to researchers involved in human disease modeling, drug discovery and development, and other applications. This workshop will bring together a panel of experts to discuss the current state of iPSC reprogramming and quality analysis. Following a 10-minute presentation by each panel member the session will be open to the audience for questions and comments.

Moderator

 Steven J. Madore, PhD, Coriell Institute for Medical Research

Speakers

 Stephen M. W. Chang, PhD,Vice President, Research and Development, The New York Stem Cell Foundation

 Karen Dyer Montgomery, PhD, FACMG, WiCell Research Institute

 Cristian A. Perez, PhD, Coriell Institute for Medical Research

 Thomas J. Novak, PhD, Cellular Dynamics International

3:00p - 4:00p  -Conference Room 3-4

Concurrent Session

Innovation Showcase

Reimbursement and Insurance for RegMed and Cell Banking Business Models

Payers hold the purse in contemporary medicine. By consequence, they demand evidence of clinical utility and cost-effectiveness before reimbursing hospitals and providers for their use of medical technologies. How and when this information is presented to the payer is incredibly important. This panel will discuss aspects of regenerative medicine and cell banking that would be of consequence to any company interested in seeking reimbursement for their technology or service.

Moderator

 Nic Anderson, MS, MBA, Medical Technology Analyst and HEOR Consultant

Speakers

 Nic Anderson, MA, MBA, Medicial Technology Analayst and HEOR Consultant

 Andrew Catton, Miller Insurance Services, LLP

 Amnon Pelz, Taburit, Cord Blood - Stem Cell Solutions

3:00p - 4:00p  -Conference Room 13-14

Concurrent Session

Discovery

Stem Cells for Oral Health

Moderator

 Christi A. Walter, PhD, The University of Texas Health Science Center, San Antonio

Speakers

 Xiao-Dong Chen, MD, PhD, StemBioSys, Inc.

 Anibal R. Diogenes, DDS, MS, PhD, University of Texas Health Science Center

4:00p - 4:15p  -Salon E Foyer

Afternoon Break

4:15p - 5:30p  -Salon E-F

Panel Discussion

Patient Groups, Foundations & Venture Philanthropy- Crucial Parties Funding Research and Delivering Therapies to Market and Patients

As traditional funding sources for both research and startups in the healthcare/bio space have become stagnant, alternative funding has begun to take up some of the slack. Higher risk endeavors are the hardest hit as fewer resources are available; the demand for an exit or ‘result’ has further compounded the effects. So where is the true risk capital? Individuals are playing an increasingly important role in the ecosystem, both influencing policy and directing funding for promising therapies and technologies in new, more targeted ways. Philanthropy is often either overlooked or misunderstood as a key source of funding. With over $240 billion in charity given by individuals in the U.S. in 2013 alone, it is critical for stakeholders to understand both the logistics and motivations that drive these funding sources.

Moderator

 Christian Braemer, Benefunder

 Angela V. Choquette, CAP, Merrill Lynch Trust Company

 Hemai Parthasarathy, PhD, Breakout Labs, The Peter Thiel Foundation

 Bernard Siegel, JD, Genetics Policy Institute

 F. Michael Wood, Jr., CFP, CIMA, Merrill Lynch

5:30p - 6:30p  -Salon E Foyer

Closing Reception!